CAELUM Cardiac Amyloid Reaching for Extended Survival&#160;A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia&#160;Treatment-Na&#239;ve Patients with Mayo Stage IIIb AL Amyloidosis<br />

CAEL101-301

Comprehensive Cancer Center Mainfranken

Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)

Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)

Phase III

Herr Dr. Maximilian Steinhardt

Herr Prof. Dr. med. Hermann Einsele

Frau Linda Heimberg

Medizinische Klinik II, Schwerpunkt Hämatologie/Onkologie

Universitätsklinikum Würzburg

Erstlinie

Therapeutisch